Table 1

Cytokine secretion by vaccine-induced lymphocytes

Vaccine3H-TdR incorporation, cpm plus and minus 1 SD
MediumERA-BPL*Negative controlPositive control
AdC68rab.gp 20 989 ± 4064 19 388 ± 3344 41 ± 10 50 149 ± 3026 
AdHu5rab.gp 3726 ± 930 4502 ± 1196 n.t. n.t. 
PSG5rab.gp 145 ± 55 1685 ± 204 28 ± 9 52 135 ± 5038 
Vaccine3H-TdR incorporation, cpm plus and minus 1 SD
MediumERA-BPL*Negative controlPositive control
AdC68rab.gp 20 989 ± 4064 19 388 ± 3344 41 ± 10 50 149 ± 3026 
AdHu5rab.gp 3726 ± 930 4502 ± 1196 n.t. n.t. 
PSG5rab.gp 145 ± 55 1685 ± 204 28 ± 9 52 135 ± 5038 

C3H/He mice were immunized with AdC68rab.gp, AdHu5rab.gp (106 pfu/mouse), or pSG5rab.gp vector (100 μg/mouse) intramuscularly. Splenocytes were harvested 2 months later and cultured at 6 × 106 lymphocytes in 24-well plates. Medium or BPL-inactivated rabies virus of the ERA strain was added at 2 μg/mL. Supernatants were harvested 24 hours later and cultured with the IL-2/IL-4–sensitive HT-2 cell line, adding 100 μL of supernatants to 2 × 103 HT-2 cells in 100 μL of medium in round-bottom microtiter plate wells. As a negative control, HT-2 cells were cultured in medium, and as a positive control they were cultured in 10% rat Concanavalin A supernatant. Tritiated-thymdine was added at 0.35 μCi/well 48 hours later for 6 hours. Cells were then harvested onto filtermats and incorporated radioactivity was measured in a beta counter. Data entries are mean incorporation of three wells plus and minus a SD.

cpm indicates counts per minute; n.t., not tested.

*

ERA-BPL in betapropiolactone-inactivated rabies virus of the Evelyn Rokithiki Abelgeth strain.

or Create an Account

Close Modal
Close Modal